Original Article

You have full text access to this OnlineOpen article

Cost-effectiveness analysis of the Lyme disease vaccine

  1. Elizabeth C. Hsia†,*,
  2. James B. Chung,
  3. J. Sanford Schwartz,
  4. Daniel A. Albert

Article first published online: 6 JUN 2002

DOI: 10.1002/art.10270

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 46, Issue 6, pages 1651–1660, June 2002

Additional Information

How to Cite

Hsia, E. C., Chung, J. B., Schwartz, J. S. and Albert, D. A. (2002), Cost-effectiveness analysis of the Lyme disease vaccine. Arthritis & Rheumatism, 46: 1651–1660. doi: 10.1002/art.10270

Author Information

  1. University of Pennsylvania, Philadelphia, Pennsylvania, USA

  1. †

    Dr. Hsia's work was supported by a Physician Scientist Development Award from the Arthritis Foundation.

*Division of Rheumatology, University of Pennsylvania, Maloney Building, Suite 504, 3600 Spruce Street, Philadelphia, PA 19104

Publication History

  1. Issue published online: 6 JUN 2002
  2. Article first published online: 6 JUN 2002
  3. Manuscript Accepted: 25 JAN 2002
  4. Manuscript Received: 26 MAR 2001

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (131K)

REFERENCES

  • 1
    Orloski KA, Hayes EB, Campbell GL, Dennis DT. Surveillance for Lyme disease—United States, 1992–1998. Mor Mortal Wkly Rep CDC Surveill Summ 2000; 49: 1–11.
  • 2
    Evans J. Lyme disease. Curr Opin Rheumatol 1999; 11: 281–8.
  • 3
    Centers for Disease Control and Prevention. Lyme disease—United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46: 531–5.
  • 4
    Gardner P. Lyme disease vaccines [editorial]. Ann Intern Med 1998; 129: 583–5.
  • 5
    Wormser GP. Vaccination as a modality to prevent Lyme disease: a status report. Infect Dis Clin North Am 1999; 13: 135–48.
  • 6
    Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, Schoen RT, et al, the Lyme Disease Vaccine Study Group. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998; 339: 209–15.
  • 7
    Steere AC. Lyme disease. N Engl J Med 2001; 345: 115–25.
  • 8
    Parenti D, Schoen R, Sennewald E, Buscarino C, van Hoecke C. Evaluation of reactogenicity and immunogenicity of booster doses of LYMErixTM, recombinant L-Osp-A vaccine against Lyme disease (LD). Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep; San Francisco (CA).
  • 9
    Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, et al, the Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease [published erratum appears in N Engl J Med 1998;339:571]. N Engl J Med 1998; 339: 216–22.
  • 10
    Maes E, Lecomte P, Ray N. A cost-of-illness study of Lyme disease in the United States. Clin Ther 1998; 20: 993–1008.
  • 11
    Magid D, Schwartz B, Craft J, Schwartz J. Prevention of Lyme disease after tick bites: a cost-effectiveness analysis. N Engl J Med 1992; 327: 534–41.
  • 12
    Centers for Disease Control and Prevention. Summary of notifiable diseases, United States, 1998. MMWR Morb Mortal Wkly Rep 1998; 47:x, 46.
  • 13
    Nichol G, Dennis DT, Steere AC, Lightfoot RW Jr, Wells G, Shea B, et al. Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis. Ann Intern Med 1998; 128: 37–48.
  • 14
    Centers for Disease Control and Prevention. Recommendations for the use of Lyme disease vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999; 48(RR-7): 1–17, 21–5.
  • 15
    Thanassi WT, Schoen RT. The Lyme disease vaccine: conception, development, and implementation. Ann Intern Med 2000; 132: 661–8.
  • 16
    Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, et al, the Infectious Diseases Society of America. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis 2000; 31 Suppl 1: S1–14.
  • 17
    Anonymous. Lyme disease vaccine. Med Lett Drugs Ther 1999; 41: 29–30.
  • 18
    CardinaleV, editor. Drug topics red book. Montvale (NJ): Medical Economics Company; 1999.
  • 19
    Lightfoot RW Jr, Luft BJ, Rahn DW, Steere AC, Sigal LH, Zoschke DC, et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease: a cost-effectiveness analysis. Ann Intern Med 1993; 119: 503–9.
  • 20
    US Bureau of Labor Statistics Web site. Consumer price indexes. Washington (DC): US Bureau of Labor Statistics; 2000. Accessed Sep. 14, 2000. URL: http://stats.bls.gov/cpihome.htm.
  • 21
    Lastavica CC, Wilson ML, Berardi VP, Spielman A, Deblinger RD. Rapid emergence of a focal epidemic of Lyme disease in coastal Massachusetts. N Engl J Med 1989; 320: 133–7.
  • 22
    Lyme disease statistics 1992–1998 [computer file]. Centers for Disease Control and Prevention; 1999.
  • 23
    Smith PF, Benach JL, White DJ, Stroup DF, Morse DL. Occupation risk of Lyme disease in endemic areas of New York state. Ann N Y Acad Sci 1988; 539: 289–301.
    Direct Link:
  • 24
    Schwartz BS, Goldstein MD. Lyme disease in outdoor workers: risk factors, preventive measures, and tick removal methods. Am J Epidemiol 1990; 131: 877–85.
  • 25
    Shadick N, Phillips C, Sangha O, Logigian E, Kaplan RF, Wright EA, et al. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med 1999; 131: 919–26.
  • 26
    Seltzer E, Gerber MA, Cartter M, Freudigman K, Shapiro E. Long-term outcomes of persons with Lyme disease. JAMA 2000; 283: 609–16.
  • 27
    Herrington JE Jr, Campbell GL, Bailey RE, Cartter ML, Adams M, Frazier E, et al. Predisposing factors for individuals' Lyme disease prevention practices: Connecticut, Maine, and Montana. Am J Public Health 1997; 87: 2035–8.
  • 28
    White DJ, Chang H-G, Benach JL, Bosler EM, Meldrum SC, Means RG, et al. The geographic spread and temporal increase of the Lyme disease epidemic. JAMA 1991; 226: 1230–6.
  • 29
    Stafford KC III, Cartter ML, Magnarelli LA, Ertel S, Mshar PA. Temporal correlations between tick abundance and prevalence of ticks infected with Borrelia burgdorferi and increasing incidence of Lyme disease. J Clin Microbiol 1998; 36: 1240–4.
  • 30
    Campbell G, Fritz C, Fish D, Nowakowski J, Nadelman R, Wormser G. Estimation of the incidence of Lyme disease. Am J Epidemiol 1998; 148: 1018–26.
  • 31
    Poland GA. Prevention of Lyme disease: a review of the evidence. Mayo Clin Proc 2001; 76: 713–24.
  • 32
    Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345: 79–84.
  • 33
    Shadick NA, Liang MH, Phillips CB, Fossel K, Kuntz KM. The cost-effectiveness of vaccination against Lyme disease. Arch Intern Med 2001; 161: 554–61.
  • 34
    Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st century: a tool for decision making. Washington (DC): National Academy Press; 1999.
  • 35
    Meltzer MI, Dennis DT, Orloski KA. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis 1999; 5: 321–8.
  • 36
    Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998; 41: 16–25.
    Direct Link:
  • 37
    Devereux RB, Frary CJ, Kramer-Fox R, Roberts RB, Ruchlin HS. Cost-effectiveness of infective endocarditis prophylaxis for mitral valve prolapse with or without a mitral regurgitant murmur. Am J Cardiol 1994; 74: 1024–9.
  • 38
    Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy ZA, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998; 281: 703–6.
  • 39
    Warner S. Patients sue over effects of vaccine. Philadelphia Inquirer. 2000 Jun 13;1, 10.
  • 40
    Food and Drug Administration. Vaccine adverse event reporting system: report for Lymerix manufactured by SmithKline Beecham. Rockville (MD): Food and Drug Administration; 2000. p. 1–51.
  • 41
    Ball R, Braun M, Lathrop S, Haber P, Mootrey GT, Hayes N. Lyme vaccine safety data reported to the vaccine adverse event reporting system (VAERS) of the USA from the first year of use [abstract]. Pharmacoepidemiol Drug Safety 2000; 9 Suppl 1: S61–2.
  • 42
    Sigal LH. Anxiety and persistence of Lyme disease. Am J Med 1995; 98 Suppl 4A: 74S–78S.
  • 43
    Sigal LH. The Lyme disease controversy: social and financial costs of misdiagnosis and mismanagement. Arch Intern Med 1996; 156: 1493–500.
  • 44
    Reid MC, Schoen RT, Evans J, Rosenberg JC, Horwitz RI. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998; 128: 354–62.
  • 45
    Coyle BS, Strickland GT, Liang YY, Pena C, McCarter R, Israel E. The public health impact of Lyme disease in Maryland. J Infect Dis 1996; 173: 1260–2.
  • 46
    Fix AD, Strickland T, Grant J. Tick bites and Lyme disease in an endemic setting: problematic use of serologic testing and prophylactic antibiotic therapy. JAMA 1998; 279: 206–10.
View Full Article (HTML) Get PDF (131K)